Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: Synthetic GnRH antagonist

Cetrorelix

Plain-language summaryIntrigue 55 / 100

Cetrorelix (Cetrotide) is a GnRH receptor blocker (rather than an agonist), approved in 2000 and used in IVF protocols to prevent the premature LH surge that would otherwise disrupt egg retrieval timing. Unlike GnRH agonists, which cause an initial flare followed by suppression, cetrorelix produces immediate dose-dependent suppression of LH and FSH with no flare. That allows brief, on-demand control of the reproductive axis without the one-to-two-week desensitization delay required of agonists. Standard IVF use is a daily 0.25 mg injection from stimulation day 5 until the trigger shot. Generally well tolerated with minor injection-site reactions. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

42/100

Canonical IVF GnRH antagonist with solid clinical evidence but mature mechanism and eroded class differentiation

Look, cetrorelix is a twenty-five year old approved drug doing exactly what it was designed to do. The GnRH antagonist mechanism here is competitive inhibition at pituitary GnRH receptors: you block the receptor, LH and FSH drop immediately, no flare. That immediate suppression without the 7-to-10-day desensitization period required by GnRH agonists like leuprolide was the whole differentiating story at approval. In 2000 it was genuinely cleaner than anything else in the category. In 2026, the story is thinner.

The evidence base is solid and we wont pretend otherwise. Multiple phase 3 trials underpinned FDA approval, the Cetrotide pivotal data replicated across European and North American centers, and the IVF literature since has been extensive. But this is a narrow clinical corridor. The signal, preventing premature LH surge in controlled ovarian stimulation, is specific enough that it doesnt port easily into other research programs. Off-label use in benign prostatic hyperplasia and prostate cancer leverages the same testosterone-flare-avoidance logic, but in those spaces, degarelix has largely taken over for the extended-suppression indication and relugolix now handles the oral route.

Here’s the thing: the GnRH antagonist class has moved on. Small-molecule oral antagonists, elagolix (endometriosis, uterine fibroids), relugolix (prostate cancer, uterine fibroids), linzagolix, have expanded the pharmacological space considerably. Cetrorelix is a subcutaneous decapeptide competing against pill-form competitors with longer duration, broader approved indications, and more current literature. On differentiation grounds its position has eroded to canonical-reference-only.

What we like: the mechanism is clean, the PK is predictable at roughly 60-hour half-life subcutaneously, and if you’re running HPG axis dynamics in a controlled ovarian stimulation model this is the standard reference tool. The flare-free profile keeps it cleaner than leuprolide for acute suppression study designs.

What we don’t like: single-receptor competitive antagonism, no multi-target angle, no novel biology. The research frontier in GnRH biology has largely shifted upstream to kisspeptin-neurokinin-dynorphin neuron work and the GPR54 axis. Cetrorelix probes the downstream output of the HPG generator, not the generator itself. For investigators trying to understand hypothalamic regulation, thats a real limitation. There’s no significant open question that cetrorelix uniquely answers in 2026. Solid workhorse for reproductive endocrinology labs, genuinely uninteresting to anyone outside that specific program.

Novelty

22

Mechanism promise

28

In-category differentiation

30

Evidence quality

70

Translational signal

70

Research bench value

45

Rationale Cetrorelix scores high on evidence and translational signal because it’s an FDA-approved drug with multiple phase 3 RCTs, but novelty and mechanism promise are low given 25 years of clinical use and straightforward single-receptor competitive antagonism. Differentiation has eroded as oral GnRH antagonists and degarelix have claimed adjacent indications.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic GnRH antagonist

A synthetic GnRH receptor antagonist used in IVF protocols to prevent premature LH surge; immediate suppression without the agonist flare.

Abstract

Cetrorelix (Ac-D-2-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2; CAS 120287-85-6; molecular formula C70H92ClN17O14; molecular weight 1431.06) is a synthetic GnRH receptor antagonist decapeptide developed at ASTA Medica and approved by the FDA in 2000 under the trade name Cetrotide. Mechanism: competitive antagonism at pituitary GnRH receptors, producing immediate dose-dependent suppression of LH and FSH without the initial flare characteristic of GnRH agonists. The antagonist mechanism allows brief, on-demand HPG suppression without the 7-to-10-day desensitization period required for GnRH agonist effect. Plasma half-life is approximately 60 hours after subcutaneous dosing. Approved for prevention of premature LH surge in controlled ovarian stimulation for IVF; the daily dose protocol begins on stimulation day 5 and continues through hCG trigger. Off-label use in benign prostatic hyperplasia and prostate cancer (where the avoidance of testosterone flare is clinically valuable). Used as the canonical GnRH antagonist in IVF research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-285Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Ganirelix

Plain-language summaryIntrigue 40 / 100

Ganirelix (Antagon, Orgalutran) is the second commercial GnRH antagonist, mechanistically identical to cetrorelix and used in the same IVF protocols for the same purpose: blocking the premature LH surge. The two drugs differ in fine structure and pharmacokinetics (ganirelix has a slightly shorter half-life), but in practice clinicians choose between them based on availability, formulation preference, and cost. Same daily dosing schedule, same side effect profile, same indication. The choice between cetrorelix and ganirelix mostly does not matter clinically. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

A me-too GnRH antagonist that’s clinically proven but offers nothing over cetrorelix for research purposes

Look, ganirelix is fine. It works in the clinic. FDA approved it in 1999, it’s in IVF protocols across the world, and if you need to suppress an LH surge in a controlled ovarian stimulation context it will do exactly that. That’s not the question. The question is whether a serious investigator should care about it as a research compound in 2026, and the honest answer is almost certainly not.

The mechanism is competitive GnRH receptor antagonism. Clean, immediate, dose-dependent LH and FSH suppression. We knew this in the late 1980s when the first-generation GnRH antagonists were being developed. Ganirelix’s structural twist versus cetrorelix, the diethylhomoarginine substitutions at positions 6 and 8, was interesting at the time as a way to reduce histamine release compared to earlier antagonists. That problem has been solved. The mechanism is completely understood and has been for two decades. There is no novel pharmacology here.

The differentiation problem is even starker. Head-to-head trials against cetrorelix show comparable efficacy. The half-life is about 13 hours versus cetrorelix’s longer profile, which is an argument for daily dosing in IVF but is not a compelling research angle. If you’re studying HPG axis suppression as a research program, cetrorelix gets you to the same answer. If you need the GnRH-receptor probe specifically, both compounds serve equally well. Ganirelix doesn’t let you ask a question you couldn’t ask with the alternative; thats the bench value test it fails.

We dont want to undersell the evidence base. Phase 2 and 3 trials exist, replication across multiple clinical groups is real, the regulatory dossier is legitimate. But clinical validation of an IVF drug’s ability to prevent premature LH surges isn’t what drives research merit in 2026. The interesting HPG research questions right now involve kisspeptin signaling, GnRH pulse dynamics in metabolic disease, and novel downstream consequences of HPG suppression in non-reproductive contexts. Ganirelix doesn’t advance any of those fronts in a unique way.

What we’re left with is a well-characterized clinical workhorse that’s interchangeable with its closest competitor for essentially any research application we can imagine. The evidence quality and translational signal scores are the only things keeping this out of the low twenties. If your program specifically requires a GnRH antagonist probe and you have ganirelix on hand, it’s not useless. As a primary research target? There’s no argument to be made.

Novelty

15

Mechanism promise

22

In-category differentiation

12

Evidence quality

70

Translational signal

65

Research bench value

28

Rationale Ganirelix scores low on novelty and differentiation because the abstract explicitly states comparable clinical efficacy to cetrorelix and an identical mechanism of action; the only structural distinction (diethylhomoarginine at positions 6 and 8 vs cetrorelix’s homoarginine) produces no meaningful pharmacological differentiation that would interest a bench investigator. Evidence quality and translational signal are solid by virtue of FDA approval and IVF clinical use, but those strengths don’t compensate for the near-zero research novelty.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic GnRH antagonist

A synthetic GnRH receptor antagonist; mechanistically similar to cetrorelix and used in the same IVF protocols.

Abstract

Ganirelix (Ac-D-2-Nal-D-Cpa-D-Pal-Ser-Tyr-D-(Et)2HArg-Leu-(Et)2HArg-Pro-D-Ala-NH2; CAS 124904-93-4; molecular formula C80H113ClN18O13; molecular weight 1570.35) is a synthetic GnRH antagonist decapeptide developed at Organon and approved by the FDA in 1999 under the trade name Antagon (US) and Orgalutran (EU). Mechanism is identical to cetrorelix: competitive GnRH receptor antagonism producing immediate dose-dependent LH and FSH suppression. Structurally distinct from cetrorelix by the diethylhomoarginine residues at positions 6 and 8. Plasma half-life is approximately 13 hours after subcutaneous dosing, shorter than cetrorelix but adequate for daily IVF protocol dosing. Approved for prevention of premature LH surge in controlled ovarian stimulation for IVF. Comparable clinical efficacy to cetrorelix in head-to-head trials. Used as an alternative GnRH antagonist in IVF and HPG suppression research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-286Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.